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ABSTRACT
We aimed to identify clinical predictors of long-term response to abiraterone 
(defined as >12 months drug exposure) in a retrospective cohort of metastatic 
castration-resistant prostate cancer patients treated in post-docetaxel setting at 24 
Italian centers. The Cox proportional hazards model was used to analyze the association 
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between clinical features and the duration of drug exposure. Results were expressed 
as hazard ratios (HR) with associated 95% confidence intervals (CI). A total of 143 
patients met the inclusion criteria. Their median age was 73 years, median Gleason 
score 8 and median abiraterone exposure 20 months. At the univariate analysis, a 
significant correlation with the duration of abiraterone exposure was found for Gleason 
score (HR 0.82, 95% CI 0.71-0.96; p=0.012), PSA (HR 1.10, 95% CI 1.03-1.18; p=0.08) 
and lactic dehydrogenase levels (HR 1.22, 95% CI 1.02-1.46; p=0.027), while the 
association between lower alkaline phosphatase levels and treatment duration was 
marginally significant (HR 1.07, 95% CI 0.99-1.16; p=0.074). Only PSA and Gleason 
score were predictive of long-term treatment duration in the multivariate analysis. No 
other clinical factors resulted to be predictive of sustained response to abiraterone, 
including metastatic disease at diagnosis and visceral disease, suggesting that all 
subgroups of patients may derive a substantial clinical benefit from abiraterone 
treatment. These findings need to be validated in prospective, larger studies.
INTRODUCTION
Treatment options for metastatic castration-resistant 
prostate cancer (mCRPC) have expanded considerably over 
the last few years, but how to select the most appropriate 
drug for each patient in order to obtain maximum benefit 
from the available therapies still remains unclear. Although 
recent studies have shown that molecular biomarkers such 
as androgen receptor splice variant-7 (AR-V7) or ERG gene 
status hold promise as potential predictors of response [1–3], 
at present there are no validated predictive biomarkers able 
to inform clinicians on best treatment selection for mCRPC 
patients [4]. Therefore, in clinical practice treatment 
strategies are decided empirically by taking into account 
mainly patient- and disease-related characteristics, as well 
as the risk-benefit ratio and the safety profile of the available 
drugs. AR axis-targeted therapies have become the mainstay 
of treatment in metastatic CRPC, both in chemotherapy-
naïve patients and in those progressing after docetaxel. 
Abiraterone, a selective inhibitor of CYP17, was the first 
available drug in this class and has been widely used in 
Europe since its approval in 2011. In the registration trial 
COU-AA-301, treatment with abiraterone plus prednisone 
significantly increased median overall survival compared 
with placebo (15.8 vs 11.2 months, HR 0.74, 95% CI 0.64-
0.86; p<0.0001) in mCRPC patients previously treated with 
docetaxel, with a median duration of abiraterone exposure 
of 7.4 months [5].
In this study we retrospectively analyzed clinical 
records of men with mCRPC who had received abiraterone 
post-docetaxel in routine clinical settings in Italy, with the 
aim to identify potential clinical predictors of long-term 
response to abiraterone, by defining long-term responders 
as those patients receiving this drug for >12 months.
RESULTS
We identified 143 patients who met the inclusion 
criteria and were evaluated. Demographic and clinical 
characteristics are summarized in Table 1. Median age 
was 73 years (range 47-87 years) and median Gleason 
score was 8 (range 3-10). The majority of patients (89%) 
had bone metastases only, and 28% had synchronous 
metastases at diagnosis. Median serum prostate-specific 
antigen (PSA), alkaline phosphatase (ALP) and lactic 
dehydrogenase (LDH) levels before starting abiraterone 
were 38 ng/dL (range 0.45-1339 ng/dL), 98.5 U/L 
(range 36-1778 U/L) and 269.5 U/L (range 113-1119 
U/L), respectively. Patients received a median of 3 prior 
lines (interquartile range [IQR] 2-4) of therapy before 
starting abiraterone, including chemotherapy (86%). 
The main reasons for treatment failure before starting 
abiraterone included PSA progression (33%), both PSA 
andradiological progression (55%) and radiological 
progression only (12%).
Median follow-up was 34.6 months and median 
duration of abiraterone treatment was 19.8 months (IQR 
14.3-29.4 months) (Figure 1). At the time of analysis, 34 
(24%) patients were still receiving abiraterone. In the 
remaining patients (72%) treatment was discontinued 
due to disease progression, while 31 (23%) had died. The 
treatment was well tolerated. The only adverse events 
which were reported were grade 1 (G1) hypokalemia 
(5%), G1-G2 asthenia (17%; G1, 14% and G2, 3%), G2 
anemia (5%), G1 mucositis (5%) and G1 diarrhea (3%). 
No G3-G4 adverse events were reported.
PSA response ≥50% was observed in 80% of 
patients (n=114), with a disease control rate of 88% 
(n=126).
Three predictors were significantly associated with 
the duration of abiraterone treatment: Gleason score 
(hazard ratio [HR] 0.82, 95% CI 0.71-0.96, p=0.012), 
PSA (the relative hazard function was time varying as 
reported in Table 2, p=0.001; unit=100 ng/dL) and LDH 
(HR 1.22, 95% CI 1.02-1.46, p=0.027; unit=100 U/L). The 
association between ALP and abiraterone exposure did not 
quite reach statistical significance (HR 1.07, 95% CI 0.99-
1.16; p=0.074; unit=100 U/L). While increasing levels of 
circulating tumor biomarkers (PSA, ALP and LDH) were 
associated with increased risk of abiraterone interruption, 
a high Gleason score was found to predict decreased risk 
of progression. No statistically significant association with 
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the duration of exposure to abiraterone emerged for age, 
M-staging at diagnosis (M0 vs M1) or site of metastases 
(bone or visceral) (Table 2). The Kaplan-Meier plots of 
abiraterone treatment duration according to LDH, Gleason 
score, PSA and ALP are reported in Figures 2–5. In the 
multivariate analysis only Gleason score and PSA were 
independent predictors of abiraterone treatment duration 
(Table 3).
DISCUSSION
The most significant finding of this study is the 
considerable proportion of heavily pre-treated mCRPC 
patients who achieved, in a routine oncology practice 
setting, a relevant clinical benefit with abiraterone. 
The duration of response exceeded, in many cases, two 
years (median 20 months). This long-term response was 
observed also in patients with unfavorable prognostic 
features such as high Gleason score, synchronous 
metastases at diagnosis or visceral disease.
A feature that sets our study apart from other similar 
investigations is the fact that we looked for potential 
clinical predictors of long-term response to abiraterone 
by focusing on a cohort of patients with a duration of 
drug exposure longer than expected (as compared with 
published data), rather than searching for factors that 
might help discriminate between responders and non/poor 
responders. The cut-off point of 12 months for definition 
of long-term response was arbitrarily selected based on 
the median abiraterone exposure of 7.4 months (range 0.2-
25.6) reported in the pivotal abiraterone COU-AA-301 
study in chemotherapy-treated patients [5].
A significant association with the duration of 
drug exposure was found for Gleason score, PSA and 
Table 1: Demographic and clinical characteristics of the study cohort
N (%) Median IQR Range
Patients 143
Age 143 73.2 47.3-87.2
Stage at diagnosis
 M0 80 (55.9)
 M1 40 (28.0)
 Missing data 23 (16.1)
Gleason score 129 8 6-10
Metastatic sites#
 Bone only 127 (88.8)
 Bone and/or other organs 12 (8.4)
 Missing data 4 (2.8)
PSA (ng/dL) 141 38 0.45-1339
ALP (U/L) 108 98.5 36-1778
LDH (U/L) 102 269.5 113-1119
Abiraterone treatment
 Duration (months) 19.8 14.3-29.4 12.0-49.0§
 Terminated 109 (76.2%)
 Ongoing 34 (23.8%)
Previous therapies
 No. of lines 143 3 2-4 1-6
 Hormonal therapy 18 (12.6%)
 Chemotherapy 123 (86.0%)
 Missing data 2 (1.4%)
*At the time of analysis; #At initiation of abiraterone treatment; §Ongoing
PSA=Prostate-specific antigen; ALP=alkaline phosphatase; LDH=Lactic dehydrogenase
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LDH levels before starting treatment, with a marginally 
significant association for ALP. The correlation between 
rising levels of circulating tumor biomarkers and poorer 
response were not surprising, given that PSA, LDH and 
ALP are known prognostic factors for survival in CRPC 
across a wide range of therapies, or in the absence of 
life-prolonging treatments [6–9]. Unexpectedly, a higher 
Gleason score was found to correlate to longer drug 
exposure. This association, however, has been documented 
in other studies, where high Gleason score was found to 
be predictive of sustained treatment response in docetaxel 
trials [10, 11] but not in the “new hormonal compounds” 
trials. In a recent retrospective analysis of the COU-
AA-301 and COU-AA-302 trials by Fizazi et al [12], 
initial Gleason score was not predictive of response to 
abiraterone in either chemotherapy naïve or post-docetaxel 
patients, as no significant difference in treatment benefits 
was found between patients with a Gleason score of < 8 
versus ≥ 8.
No other potential predictors of long-term 
response emerged from our analysis. In particular, the 
presence of synchronous metastases at diagnosis and 
visceral disease were not associated with a less favorable 
outcome (although only 8.4% of patients had visceral 
metastases in our cohort). The lack of a significant 
association between presence of visceral metastases 
and radiological progression or survival has been 
observed in other recent retrospective studies in patients 
treated with AR-targeted therapies [13, 14]. These 
findings are in keeping with the results of subgroup 
and exploratory post-hoc analyses of the COU-AA-301 
trial and suggest that all subgroups of patients are likely 
to derive at least some clinical benefit (not excluding 
the possibility of a long-term benefit) from abiraterone 
treatment, irrespective of unfavorable baseline clinical 
characteristics [5, 15]. Furthermore, most of our patients 
had skeletal metastases only, and they might well 
represent ideal candidates for abiraterone treatment, 
as suggested by recent data documenting direct bone 
anabolic and anti-resorptive effects of this drug both in 
vitro and in CRPC patients [16].
Our study had limitations that need to be taken 
into account when interpreting the results, including 
the retrospective design and the relatively small 
patient population. The lack of a control group of 
early refractory patients did not allow to discriminate 
between early refractory and long responding patients. 
Moreover, we evaluated outcome based on abiraterone 
exposure time rather than using standardized outcome 
measures such as overall survival (OS) or progression-
free survival (PFS).
Several biomarkers have been recently proposed 
as potential predictors of treatment response in 
mCRPC, including tumor-associated genetic profiling 
parameters from biopsies, circulating biomarkers, 
imaging data and clinical variables. AR-V7 has been 
linked to primary resistance to either abiraterone 
or enzalutamide, and monitoring AR-V7 status in 
circulating tumor cells (CTCs) over the course of 
treatment may predict sensitivity or resistance to AR-
Figure 1: Kaplan-Meier plots of duration of treatment with abiraterone.
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targeted agents [1, 2]. Analysis of AR-modulated ERG 
expression in archival tumor biopsies from patients 
enrolled in the COU-AA-302 trial showed that ERG 
gene fusion expression (2+ Edel cancers), previously 
considered as unfavorable prognostic factor for 
survival, was associated with the greatest clinical 
benefit from abiraterone treatment [17]. Imaging 
biomarkers may also assist in therapeutic monitoring 
and outcome prediction, as suggested by the results of 
a pilot study on the use of 18-F fluorocholine positron 
emission tomography/computed tomography (FCH-
PET/CT) in early evaluation of abiraterone response 
in the post-docetaxel setting [18]. Nevertheless, the 
lack of standardization, the limited availability and 
the cost of the newer imaging modalities are still 
an issue. Among circulating biomarkers, CTCs and 
neutrophil/lymphocyte ratio (NLR, a manifestation of 
tumor-promoting inflammation) have been shown to 
be prognostic in many cancer types and are receiving 
much attention in the context of mCRPC [6, 19]. A 
biomarker panel based on CTCs count and LDH was 
shown to meet the Prentice criteria as a surrogate for 
OS in the COU-AA-301 trial, and validation studies 
are ongoing [20]. On the other hand, preliminary data 
suggest that a 30% decline in CTCs levels 4 weeks 
after treatment initiation from baseline may predict 
treatment response to abiraterone or chemotherapy 
in patients with mCRPC [21]. In a cohort of mCRPC 
patients treated with abiraterone in a Canadian study 
(53% post-docetaxel), Leibowitz-Amit et al. identified 
a composite score derived from the sum of baseline 
NLR and the extent of metastatic spread as a predictor 
of PSA response [22]. Preliminary data have also shown 
that an increase in NLR persisting during enzalutamide 
treatment in chemotherapy-treated mCRPC patients 
may predict a poor response to enzalutamide [23].
Retrospective analysis of the Temporary 
Authorization for Use programme in France showed that 
PSA decrease at 3 months was a predictive factor for 
abiraterone treatment duration [24]. In our experience 
we could not explore this correlation because of 
different timepoints for PSA evaluation. Among clinical 
biomarkers, the duration of previous androgen-deprivation 
therapy (ADT) response, or time to CRPC, has received 
much attention as a potential predictor of response to the 
new AR-targeted therapies. In a retrospective study in 61 
mCRPC patients treated with abiraterone post-docetaxel, 
Ashfar et al. identified three independent predictors of 
OS: hemoglobin levels, ECOG-PS at starting abiraterone, 
and duration of response to primary androgen-deprivation 
therapy [13]. Similarly, time to CRPC ≥12 months and 
ECOG-PS score 0-1 were associated with improved PFS 
in a cohort of 173 patients treated with enzalutamide, 
abiraterone or other hormonal therapies at two French 
cancer centers [14]. The duration of previous hormonal 
therapy resulted to be associated with better OS also in the 
Table 2: Univariate analysis of duration of treatment with abiraterone
Parameter HR point estimate 95% CI p-value
Continuous variables
Age (years)* 1.05 0.81-1.37 0.722
Gleason score 0.82 0.71-0.96 0.012
PSA# 1.00 0.89-1.13 0.001
Linear interaction term with time° 1.03 1.01-1.06
ALP# 1.07 0.99-1.16 0.074




0.733 M1 0.92 0.59-1.45
Metastatic sites
 Bone only 1
0.526 Other 0.80 0.40-1.59
° Time 0 in the Cox model: 12 months
*Relative risk of terminating treatment for each 10 years of age; #Unit divided by 100
PSA=prostate-specific antigen; ALP=alkaline phosphatase; LDH=lactic dehydrogenase
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Figure 3: Kaplan-Meier plots of duration of treatment with abiraterone according to Gleason score.
Figure 2: Kaplan-Meier plots of duration of treatment with abiraterone according to LDH levels.
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Figure 4: Kaplan-Meier plots of duration of treatment with abiraterone according to PSA levels.
Figure 5: Kaplan-Meier plots of duration of treatment with abiraterone according to ALP levels.
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abiraterone-treated cohort (n=306) of the aforementioned 
Temporary Authorization for Use study [24]. Furthermore, 
time to development of CRPC was identified as the 
strongest predictor of PSA response, PSA-PFS and OS 
also when AR-targeted therapies were used in a second 
line setting, as reported in a retrospective study evaluating 
the outcome of 126 patients treated with sequential 
abiraterone and enzalutamide [25]. Other studies, however, 
failed to identify a significant association between duration 
of previous androgen-deprivation therapy and response to 
subsequent AR-targeted treatments (including the cited 
investigation by Leibowitz-Amit et al.) [22]. In our study, 
data about the duration of previous hormonal treatment 
were not always available for analysis and therefore we 
could not explore this factor.
It should be emphasized that none of the biomarkers 
so far investigated have yet been validated as predictors of 
treatment response [4, 6].
In conclusion, our retrospective analysis in patient 
with mCRPC, mostly treated in post-docetaxel setting, 
showed that high Gleason score, lower PSA and LDH 
levels before starting abiraterone were significantly 
associated with long-term abiraterone exposure (a 
marginal significance being found for lower ALP). We 
failed to identify more specific clinical factors predictive 
of sustained response to this drug, suggesting that all 
suitable patients may receive abiraterone therapy on 
the basis of clinical or tumor-related characteristics. 
Prospective studies in larger patient populations are 
needed to confirm our findings.
MATERIALS AND METHODS
Patients with histologically confirmed mCRPC who 
were treated with abiraterone for >12 months at 24 Italian 
cancer centers from October 2011 to July 2014 were 
retrospectively identified. Clinical records were collected 
and the following demographic and clinical parameters 
were analyzed: age at initial abiraterone exposure, duration 
of abiraterone treatment, number and type of previous 
anticancer therapies, serum levels of PSA, ALP and LDH 
before starting abiraterone, Gleason score at diagnosis, 
type of disease progression before starting abiraterone 
(PSA progression only or radiological progression), 
M-staging at diagnosis, sites of metastases, PSA response 
rates and objective response (in men with measurable 
disease). The study endpoint was the time from the start 
of abiraterone treatment to abiraterone interruption from 
any cause. Patients’ data were collected for retrospective 
analysis in April 2015.
Statistical analysis
Descriptive statistics were used to summarize 
demographic and clinical features (median, IQR 
and range for continuous variables, absolute and 
percentage frequencies for categorical variables). The 
Cox proportional hazards model was used to detect 
and estimate the statistical association between the 
patients’ demographic-clinical features and the duration 
of abiraterone exposure; the hazard ratio (HR) was used 
as population parameter and the Wald test statistic was 
used to test H0: HR = 0. All statistical tests were two-
sided and statistical significance was detected at the 
5% probability level (p-value<0.05). For each predictor 
the assumption of proportional hazard was tested using 
a Cox’s model with a constant and linear term in time. 
For each continuous predictor associated to abiraterone 
treatment duration the best thresholds were identified 
using the CART methodology [26], with regression trees 
being generated by means of the Recursive Partitioning 
and Regression Trees (Rpart) package. Each tree was 
pruned back in order to avoid data overfitting and the tree 
size that minimized the cross-validated error was chosen. 
At least one threshold was mandatory. A backward 
elimination Cox regression procedure at 0.05 level was 
used to identify the strongest predictors of abiraterone 
treatment duration.
The Kaplan-Meier method was used to estimate 
survival functions. The inverse Kaplan-Meier method 
was used to estimate median follow-up; patients still 
receiving abiraterone at the time of the last contact were 
right censored.
Apart from CART methodology, the statistical 
analysis was performed using the SAS software (SAS 
Institute, Cary, NC, USA), version 9.2.
Table 3: Multivariate analysis of duration of treatment with abiraterone†
Parameter HR point estimate 95% CI p-value
Gleason score 0.84 0.72-0.98 0.029
PSA# 0.96 0.84-1.10 0.006
Linear interaction term with time° 1.04 1.01-1.07
† Gleason score, PSA, ALP, LDH were introduced as candidate predictors in the backward selection Cox model
° Time 0 in the Cox model: 12 months
#Unit divided by 100
PSA=prostate-specific antigen; ALP=alkaline phosphatase; LDH=lactic dehydrogenase
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